Results 91 to 100 of about 50,850 (292)
Psoriatic Arthritis Registries
The Journal of Rheumatology Supplement, 2015 The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics ...
Sarzi-Puttini, Piercarlo +4 more
openaire +3 more sources
Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.Purpose To evaluate the literature regarding the efficacy of various repair and reconstruction surgical techniques for chronic quadriceps tendon ruptures (QTRs) in native knees and to assess their associated outcomes. Methods A comprehensive literature search of the EMBASE, PubMed/MEDLINE, and Cochrane databases was conducted from October 2023 to ...
Matthew R. Bryan +8 more
wiley +1 more source
Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland [PDF]
, 2016 Objective : The objective of the study was to analyse the prevalence of psoriatic arthritis (PsA) in Poland and to assess the costs generated by treatment of PsA patients in the system of public healthcare. Material and methods : The analysis was based
Brygida Kwiatkowska +5 more
core +1 more source
Etanercept in Psoriatic Arthritis
The Journal of Rheumatology Supplement, 2012 In this update on etanercept (ETN) in psoriatic arthritis (PsA) we analyze this drug's mechanism of action, clinical efficacy/effectiveness, optimal dosage, disease-modifying antirheumatic drugs (DMARD) association, radiological progression, safety, switching aspects, and pharmacoeconomy.
Spadaro A +3 more
openaire +5 more sources
Arthritis &Rheumatology, EarlyView.Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie +12 more
wiley +1 more source
Local effects of adipose tissue in psoriasis and psoriatic arthritis [PDF]
, 2017 Ilja L Kruglikov,1 Uwe Wollina2 1Scientific Department, Wellcomet GmbH, Karlsruhe, 2Department of Dermatology and Allergology, Hospital Dresden-Friedrichstadt Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany Abstract ...
Wollina U, Kruglikov IL
core
IS PSORIATIC ARTHRITIS REALLY PSORIATIC? [PDF]
, 2014 The paper discusses the apparent rhetorical question whether psoriatic arthritis is psoriatic. Based on the data available in the literature and logical considerations, it has been suggested that accepted view may be contrary to ...
Sh. F. Erdes
core +2 more sources
Choosing the right treatment for patients with psoriatic arthritis [PDF]
, 2020 Psoriatic arthritis (PsA) is a chronic inflammatory condition with articular and extra-articular manifestations: peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, inflammatory bowel disease and uveitis. Anti-tumour necrosis factors (
Nash, P +3 more
core +1 more source
CLINICAL OUTCOME MEASURES OF PSORIASIS
Reumatismo, 2011 Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present specific advantages and limitations.
E. Berardesca, C. Bonifati
doaj +1 more source
The Journal of Rheumatology Supplement, 2009 Early detection of psoriatic arthritis (PsA) can effectively help in reducing the risk of joint damage and disability. Accordingly, the authors offer diagnostic insights in order to improve the approach to the patient's medical history, clinical examination, and the imaging modalities.
Scarpa R. +6 more
openaire +4 more sources